ALR Technologies (OTCBB: ALRT) announces that it has received notice from the US Patent and Trademark Office that ALRT has been granted approval of its patent application regarding patient compliance and remote monitoring of patient's use of nebulizer compressors. This approval from the US patent office will protect ALRT's Health-E-Connect health management communications system and more importantly, will grant ALRT the exclusive ability to remotely monitor the use of nebulizer compressors in the delivery of medications to patients with COPD, chronic asthma and cystic fibrosis.
COPD is one of the leading causes of death in the world. With 16 million people in the US with COPD and 20 million plus with asthma, utilizing ALRT's Health-E-Connect system to monitor their use of nebulizer compressor creates the opportunity to significantly improve quality of life and reduce healthcare costs. Health Professionals will now be able to remotely monitor and evaluate compliance in delivery of aerosolized medications to their patients with respiratory diseases thereby helping these patients to reduce health complications and improve their quality of life.
The use of monitoring-ready nebulizer compressors and ALRT's Health-E-Connect health management communications system can become an important new service provided by health professionals. Furthermore, the Health-E-Connect system is on target with the growing recognition in the US to use electronic health records to improve the efficiency and effectiveness of patient care.
ALRT announced earlier this year that insurance carriers will reimburse physicians for the remote care of patients with the use of its Health-E-Connect system. This will result in new revenue for physicians as they provide the additional service to their patients with respiratory disease. ALRT's Health-E-Connect and complementary Constant Health Companion is the only system in the US and International markets that allows for remote monitoring of patients' use of nebulizer compressors. This capability will allow for enhanced patient compliance and health professional coordination of care.
Recruitment underway for a clinical trial testing new vaccine against respiratory viruses